Annual Accounts Receivable
$72.44 M
+$31.29 M+76.04%
31 December 2022
Summary:
Eagle Pharmaceuticals annual accounts receivable is currently $72.44 million, with the most recent change of +$31.29 million (+76.04%) on 31 December 2022. During the last 3 years, it has risen by +$21.32 million (+41.71%). EGRX annual accounts receivable is now at all-time high.EGRX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$115.14 M
+$187.00 K+0.16%
30 June 2023
Summary:
Eagle Pharmaceuticals quarterly accounts receivable is currently $115.14 million, with the most recent change of +$187.00 thousand (+0.16%) on 30 June 2023. EGRX quarterly accounts receivable is now -12.01% below its all-time high of $130.86 million, reached on 31 March 2022.EGRX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EGRX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | +41.7% | +144.6% |
| 5 y5 years | +8.9% | +156.9% |
EGRX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +76.0% | -12.0% | +179.8% |
| 5 y | 5 years | at high | +76.0% | -12.0% | +179.8% |
| alltime | all time | at high | +4482.4% | -12.0% | +2147.1% |
Eagle Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| June 2023 | - | $115.14 M(+0.2%) |
| Mar 2023 | - | $114.95 M(+58.7%) |
| Dec 2022 | $72.44 M(+76.0%) | $72.44 M(-25.3%) |
| Sept 2022 | - | $96.93 M(+12.8%) |
| June 2022 | - | $85.92 M(-34.3%) |
| Mar 2022 | - | $130.86 M(+218.0%) |
| Dec 2021 | $41.15 M(-19.5%) | $41.15 M(-12.6%) |
| Sept 2021 | - | $47.08 M(-10.6%) |
| June 2021 | - | $52.66 M(+17.4%) |
| Mar 2021 | - | $44.87 M(-12.2%) |
| Dec 2020 | $51.12 M(+6.5%) | $51.12 M(-2.1%) |
| Sept 2020 | - | $52.20 M(+11.6%) |
| June 2020 | - | $46.78 M(-14.1%) |
| Mar 2020 | - | $54.49 M(+13.5%) |
| Dec 2019 | $48.00 M(-27.8%) | $48.00 M(+7.1%) |
| Sept 2019 | - | $44.81 M(-25.7%) |
| June 2019 | - | $60.34 M(-5.6%) |
| Mar 2019 | - | $63.93 M(-3.8%) |
| Dec 2018 | $66.49 M | $66.49 M(-15.3%) |
| Sept 2018 | - | $78.46 M(+13.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2018 | - | $69.40 M(+29.9%) |
| Mar 2018 | - | $53.43 M(-0.7%) |
| Dec 2017 | $53.82 M(+27.6%) | $53.82 M(-24.8%) |
| Sept 2017 | - | $71.60 M(+34.5%) |
| June 2017 | - | $53.23 M(-37.2%) |
| Mar 2017 | - | $84.74 M(+100.8%) |
| Dec 2016 | $42.19 M(+60.6%) | $42.19 M(-10.3%) |
| Sept 2016 | - | $47.05 M(-9.6%) |
| June 2016 | - | $52.03 M(+96.1%) |
| Mar 2016 | - | $26.53 M(+1.0%) |
| Dec 2015 | $26.27 M(+260.0%) | $26.27 M(+115.0%) |
| Sept 2015 | - | $12.22 M(-5.9%) |
| June 2015 | - | $12.98 M(+23.5%) |
| Mar 2015 | - | $10.51 M(-12.1%) |
| Dec 2014 | - | $11.96 M(+63.9%) |
| Sept 2014 | $7.30 M(+42.4%) | $7.30 M(+8.7%) |
| June 2014 | - | $6.71 M(-14.2%) |
| Mar 2014 | - | $7.82 M(+18.6%) |
| Dec 2013 | - | $6.59 M(+28.7%) |
| Sept 2013 | $5.12 M(+224.1%) | $5.12 M |
| Sept 2012 | $1.58 M | - |
FAQ
- What is Eagle Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Eagle Pharmaceuticals?
What is Eagle Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of EGRX is $72.44 M
What is the all time high annual accounts receivable for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high annual accounts receivable is $72.44 M
What is Eagle Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of EGRX is $115.14 M
What is the all time high quarterly accounts receivable for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high quarterly accounts receivable is $130.86 M